Equities

Lumiera Health Inc

NHP.H:NEX

Lumiera Health Inc

Actions
  • Price (CAD)0.005
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change--
  • Beta1.3136
Data delayed at least 15 minutes, as of Apr 17 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Lumiera Health Inc. is a Canada-based natural health products company. The principal business of the Company is that of selling natural and homeopathic products. The Company specializes in the development and commercialization of evidence-based botanical products for the healthcare industry. The Company sells both oral and topical botanical agents to help manage unmet medical needs through its Holizen Laboratories division. It is also developing and commercializing a portfolio of innovative solutions in high growth categories such as sleep-aids and pain management. Its product's portfolio categories such as topical pain relief, sleep, skin care, women's health, & infections. The Company’s products and brands include Holizen, Awaye pain relief cream and Bazzzics. The Holizen portfolio has over 20 products that cover a range of therapeutic needs, including cardiovascular health; stress relief; bones, joints & muscle mobility; energy and immunity.

  • Revenue in CAD (TTM)592.10k
  • Net income in CAD-2.36m
  • Incorporated2013
  • Employees--
  • Location
    Lumiera Health Inc4500 Blvd. KimberSAINT-HUBERT J3Y 8K5CanadaCAN
  • Phone+1 (450) 926-2442
  • Fax+1 (450) 926-2452
  • Websitehttps://www.lumiera.ca/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Zenith Capital Corp0.00-23.08m775.71k-----------0.1576-0.15760.00-0.170.00-------339.76-----------------9.97---------68.27------
Well Told Company Inc-100.00bn-100.00bn781.13k-----------------0.0053------------------------0.3492--2.27--------------
Psybio Therapeutics Corp0.00-3.85m838.96k4.00---------0.0331-0.03310.00-0.01810.00-------357.70-----------------617.30--------55.66------
Lumiera Health Inc592.10k-2.36m844.39k--------1.43-0.0139-0.01390.0035-0.01360.50962.1311.78---202.92------13.17---398.18--0.0395-2.10----46.91---188.58------
NeutriSci International Inc59.98k-552.46k890.88k--------14.85-0.0032-0.00320.0003-0.00510.29881.3311.47---275.23-288.65-----43.90-7.95-921.07-1,046.330.0059------465.8924.8250.98------
Hill Inc2.16m-1.91m902.44k----0.8735--0.4176-0.5883-0.58830.66650.31480.446154.885.54---39.40-77.46-44.59-101.0370.6250.14-88.31-153.933.42-3.860.7205---10.2333.8618.26--16.21--
Claritas Pharmaceuticals Inc0.00-2.62m956.42k-----------0.0851-0.20370.000.12660.00-------17.49-33.39-51.79-39.16----------6.860.1409------119.85------
Data as of Apr 17 2023. Currency figures normalised to Lumiera Health Inc's reporting currency: Canadian Dollar CAD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.